EUR 227 million share buyback begins Schiphol, January 12, 2026 - Aegon today begins a EUR 227 million share buyback, which includes EUR 200 million of the EUR 400 million on December 10, 2025. This tranche has been expanded to include EUR 27 million to meet Aegon’s obligations resulting from its share-based compensation plans for senior management. The share buyback is expected to be completed by June 30, 2026, barring unforeseen circumstances. Aegon has entered into an agreement with its largest shareholder, Vereniging Aegon, to participate in the new EUR 227 million share buyback. Ver...
We hosted our 29th ODDO BHF Forum in Lyon on 8 and 9 January 2026. In total, 220 companies presented over the two days. In the following note, we provide some initial feedback from the companies on Day 2, in addition to Day 1 feedback (Link to Day 1 feedback). Key positive companies were Corbion, DEME, Elia Group, Knorr Bremse, Sulzer, Séché Environnement, Fraport, Vallourec and TUI. More cautious companies were Arkema, Fastned, INWIT, Manitou, Roche Bobois, Téléperformance, and Colonial SFL. T...
Inside information: Fagron announces the completion of the acquisition of University Compounding Pharmacy in North America Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 January 2026 – 7:00 AM CET Fagron announces the completion of the acquisition of University Compounding Pharmacy in North America Fagron, the leading global player in pharmaceutical compounding, is pleased to announce the completion of University Compounding Pharmacy (UCP), a 503A pharmaceutical compounder focused on the health and wellness segment in California. The transacti...
Voorkennis: Fagron kondigt de afronding van de overname van University Compounding Pharmacy in Noord-Amerika aan Gereglementeerde informatie - voorkennisNazareth (België)/Rotterdam (Nederland), 12 januari 2026 – 7:00 AM CET Fagron kondigt de afronding van de overname van University Compounding Pharmacy in Noord-Amerika aan Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, kondigt met genoegen de afronding van de overname van University Compounding Pharmacy (UCP), een 503A-farmaceutisch bereider gericht op de gezondheids- en welzijnssector in Californië, aan. De t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.